Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Medical Device Safety Concerns Rheumatologists

Kurt Ullman  |  Issue: December 2011  |  December 12, 2011

Over the years, there have been a number of highly publicized instances where medical devices allowed to enter the market were later found to fail at higher-than-expected rates. While rheumatologists don’t implant medical devices, they do have an interest in how these devices work—and that they work well—because they may recommend the use of prosthetic joints and other kinds of medical devices to their patients.

“Among the various devices coming under question in recent years, there has been a significant concentration in the orthopedic realm,” says C. Ronald MacKenzie, MD, associate professor of clinical medicine (rheumatology and medical ethics) at the Hospital for Special Surgery, the Weill-Cornell Medical Center in New York. “These concerns are therefore relevant for the patients we look after as rheumatologists.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Three Risk Categories

Requirements that makers of medical devices notify the Food and Drug Administration (FDA) before marketing a new product were established under section 510(k) of the Federal Food, Drug, and Cosmetic Act passed in 1938. The process in place today started following passage of the Medical Device Amendments Act in 1976.

The FDA has classified medical devices into three categories, according to their level of risk. “Class I presents the lowest risk and are exempt from any type of premarket approval [PMA],” says David Challoner, MD, vice president for health affairs emeritus of the University of Florida in Gainesville. “These are things like tongue depressors. They go directly to market after their manufacturing processes are reviewed and approved.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The middle category, Class II, is by far the biggest group, with 90% of all devices authorized for market falling under this umbrella.1 These devices are thought to pose some risk to the consumer but can usually be marketed after submitting PMAs, called 510(k) applications after the section of the law, showing their “substantial equivalence” to another legally marketable device.

Class III devices pose the highest level of risk and must establish both safety and efficacy. This is the only level with that requirement, and generally requires PMA.

Substantial Equivalence

To understand both the reality and the concerns about the current 510(k) process, you have to understand the concept of substantial equivalence.

“Ford comes up with a new car that has an engine, four tires, seats; while there are some cosmetic differences they are not really all that different from other cars at the mechanical level,” says Matthew Kraay, MD, Kingsbury G. Heiple and Fred A. Lennon Professor of Orthopaedics, Case Western Reserve University, Cleveland. “Most devices are approved that way. You only have to point to something that was approved in the past, called a ‘predicate device,’ and convince the FDA that yours is the same as the earlier one.”

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:FDAmedical deviceRegulationrheumatologistSafety

Related Articles

    Cobalt Toxicity Complication of Hip Replacement Surgery

    September 1, 2014

    Rheumalogists urged to recognize toxicity symptoms in patients with metal-on-metal or metal-on-polyethylene hip implants

    High-Risk Medical Devices Backed by Few Studies

    August 12, 2015

    (Reuters Health)—Many high-risk therapeutic devices get U.S. Food and Drug Administration (FDA) approval with only one study proving their safety and efficacy before going to market. Studies of how the devices work once they are on the market are also few and far between, according to a new study that looked at all 28 high-risk…

    Institute of Medicine Recommends Changes in Graduate Medical Education

    June 15, 2015

    Questions, concerns and spirited debate have surrounded the Graduate Medical Education (GME) system for decades. The program that trains nearly 120,000 physicians per year is under constant scrutiny.1 Changes to the political landscape, combined with ongoing efforts by health industry payers and regulators to squeeze inefficiency out of the system, have kept the GME in…

    Many Medical Devices Hit the Market before Safety Studies Are Published

    June 5, 2016

    (Reuters Health)—Medical devices approved by the U.S. Food and Drug Administration (FDA) are often cleared before studies on their safety or effectiveness have been released to the public, a report suggests. Without published data, doctors and patients may not be able to make informed decisions about whether to use the products, the authors warn. ad…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences